• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$1.56 -$0.04 (-2.50%)

REAL-TIME: Last trade at

Prana Biotechnology Limited (A...

NASDAQ:PRAN

Jump to this page for:

Related Resources

Prana Chief Scientific Advisor to Give Plenary Lecture at Alzheimer's Symposium in Stockholm Featuring New Targets and Drugs

5/9/2012 by Marketwire

Prana Comments on Archives of Neurology Publication Which Highlights Critical Role of Brain Metals in Huntington Disease Progression

5/1/2012 by Marketwire

Prana enrolls 1st patient in Reach2HD Phase II Huntington Disease trial

4/30/2012 by Theflyonthewall.com

Prana Enrolls First Patient in the "Reach2HD" Phase II Huntington Disease Trial

4/30/2012 by Marketwire

PLoS ONE Journal Publishes Mechanistic Model of Alzheimer's Disease Endorsing Prana's PBT2

3/26/2012 by Marketwire

Prana Doses First Patient in the "IMAGINE" Phase II Alzheimer's Disease Trial

3/7/2012 by Marketwire

Prana Comments on Nature Medicine, PNAS and Journal of Alzheimer's Disease Articles That Highlight the Role of Metals in Neurological Diseases

2/2/2012 by Marketwire

Professor Rudy Tanzi Appointed Prana's Chief Scientific Advisor

1/11/2012 by Marketwire

Prana receives FDA approval to commence Huntington's Disease trial

1/4/2012 by Theflyonthewall.com

FDA Approval to Commence Huntington's Disease Clinical Trial Using Prana's PBT2

1/4/2012 by Marketwire

Landmark Publication Endorses Prana's Drug Pipeline Strategy for Treating Neurodegenerative Diseases

12/16/2011 by Marketwire

Prana Biotech Begins Recruiting For Phase II Study Of PBT2 To Treat Alzheimer's

12/15/2011 by RTTNews

Prana commences Alzheimer's trial recruitment

12/15/2011 by Theflyonthewall.com

Prana Commences Alzheimer's Trial Recruitment

12/15/2011 by Marketwire

Prana secures key patent for Parkinson's drug PBT434 in the U.S.

11/28/2011 by Theflyonthewall.com

Prana Secures Key Patent for Parkinson's Drug PBT434 in the United States

11/28/2011 by Marketwire

Prana Biotechnology (PRAN) Receives Approval by Austin Health Research Ethics Committee for Alzheimer's Trial

11/22/2011 by StreetInsider.com

Prana receives approval for Alzheimer's trial

11/22/2011 by Theflyonthewall.com

Prana Receives Approval for Alzheimer's Trial

11/22/2011 by Marketwire

Prana says PBT2 reverses loss of synaptic activity in neurons

11/14/2011 by Theflyonthewall.com

PRANA's PBT2 Reverses the Loss of Synaptic Activity in Neurons

11/14/2011 by Marketwire

Australian Federal Government Funds Study Into Neuroprotective Benefits of Prana's PBT2

10/27/2011 by Marketwire

Australian Federal Government Grant to Study Effect of PBT2 in the Ageing Brain

10/20/2011 by Marketwire

McNicoll Lewis & Vlak Starts Prana Biotechnology (PRAN) at Buy; Novel Therapeutic Approach to CNS Disorders: Neuronal Metal Homeostasis

10/4/2011 by StreetInsider.com

Prana rises 18%

9/19/2011 by Theflyonthewall.com

Prana announces Journal of Neurochemistry publication on PBT2

9/19/2011 by Theflyonthewall.com

Prana's Planned Huntington's Trial Receives Strong Interest From Patients and Researchers

9/15/2011 by Marketwire

World Congress on Huntington's Learns About PBT2's Promise

9/13/2011 by Marketwire

PBT2 Huntington's Disease Trial Presented at World Congress on Huntington's Disease in Melbourne

9/12/2011 by Marketwire

Prana receives Michael J. Fox Foundation grant to develop PBT434 for Parkinson's

8/22/2011 by Theflyonthewall.com

Prana Receives Michael J. Fox Foundation Grant to Develop PBT434 for Parkinson's Disease

8/22/2011 by Marketwire

Leading Biotechnology Investor Lawrence Gozlan Joins Prana's Board of Directors

8/8/2011 by Marketwire

PBT2's 'Mechanism of Action' Presented in a Plenary Lecture at International Conference on Alzheimer's Disease (ICAD) on July 21 in Paris

7/21/2011 by Marketwire

files to sell up to 5M ADS through at-the-market offering

7/14/2011 by Theflyonthewall.com

Prana Announces At-The-Market Issuance Program

7/13/2011 by Marketwire

Quintiles Makes Second Investment in Prana

6/30/2011 by Marketwire

Prana's PBT2 Presented at the Huntington's Disease Society of America National Convention

6/28/2011 by Marketwire

Rodman & Renshaw Provides Color on Prana Biotechnology, Market Outperform

6/15/2011 by Benzinga

Prana's Founding Scientists Present Findings at World Pharma Congress

6/7/2011 by Marketwire

Prana Biotech (PRAN) Files $50M Mixed Securities Shelf

5/17/2011 by StreetInsider.com
See More Articles...